Amyotrophic Lateral Sclerosis Non-invasive Ventilation Exchange

Amyotrophic Lateral Sclerosis Clinical Trial

— ANEX  

Official title:

Contribution of a Multimodal Digital Platform in the Management and Follow-up of Patients With Amyotrophic Lateral Sclerosis Treated With Non-invasive Ventilation: Randomized Controlled Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05837507
• Other study ID #: RECHMPL23_0054
• Status: Recruiting
• Phase: N/A
• Start date: July 5, 2023
• Est. completion date: May 2025

Study information

• Verified date: April 2023
• Source: University Hospital, Montpellier
• Contact: Francois BUGHIN, MD
• Phone: 04.67.33.82.84
• Email: f-bughin[@]chu-montpellier.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The median survival of patients with amyotrophic lateral sclerosis (ALS) is 3 to 5 years and mortality is mainly related to respiratory failure. Non-invasive ventilation (NIV) and multidisciplinary management improve the quality of life and survival of patients. However, patients have mobility difficulties related to the progressive worsening of functional disabilities. The research team hypothesize that the use of a multimodal digital platform, including in particular telemonitoring of NIV and teleconsultation, will slow down the evolution of the disabilities of patients with ALS and improve their quality of life.

Description:

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with a median life expectancy of 3 to 5 years. Respiratory failure due to alveolar hypoventilation is the main cause of mortality and respiratory impairment leads to a significant deterioration in quality of life.

Non-invasive ventilation (NIV) improves patient quality of life, improves gas exchange and improves patient survival. NIV should be initiated early, based on symptomatology and lung function, and monitored closely to adjust device parameters. NIV is a complex intervention that must be individualized for each patient.

In addition, multidisciplinary management involving different healthcare professionals, keeping the patient and caregivers at the center of the network, also allows for an improvement in the quality of life and survival of these patients.

However, patients with ALS have difficulty moving around and access to care becomes more complicated as the disease progresses. This phenomenon was increased during the COVID- 19 pandemic with a more rapid functional decline.

The development of new technologies should make it possible to rethink patient management, in particular through remote monitoring of NIV devices, teleconsultation, administration of questionnaires and better interprofessional organization. Several studies have confirmed the feasibility and acceptance of telemedicine solutions in this population.

In this project, The research team hypothesize that the use of a multimodal digital platform will slow the progression of disability in ALS patients and improve their quality of life, in particular by improving the quality of NIV and optimizing the coordination of a multidisciplinary team.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 58
• Est. completion date: May 2025
• Est. primary completion date: November 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patients between 30 and 85 years old

• Diagnosis of ALS

• Indication and acceptance of non-invasive ventilation

• Patient equipped with suitable equipment (tablet, computer, telephone, etc.) with an internet connection at home

• Patient able to read and understand the procedure, and able to express consent for the study protocol

Exclusion Criteria:

• Treatment with non-invasive ventilation in the previous three months

• Refusal/inability to use a smart phone or digital device

• Patient currently participating or having participated in the month preceding inclusion in another clinical interventional research that could impact the study, this impact is left to the discretion of the investigator.

• Subject under guardianship or curators

• Subject not affiliated to a social security scheme, or not a beneficiary of such a scheme.

• Subject deprived of liberty by judicial or administrative decision

• Pregnant, parturient, breastfeeding women

• Refusal to give consent

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Other:
• Telerehabilitation solution (m-Rehab)
Patients in the experimental group will have access to a multimodal digital platform (m-Rehab®). The solution includes a website and an application available on smart phones for the patient and caregivers. Patients and caregivers will have access to educational content about the condition and its treatments, NIV compliance data, digital group educational workshops, secure messaging and video conferencing. All the professionals forming the patient's circle of care will be able to have access to the solution, after the patient's authorization. The circle of care, in a non-exhaustive way, includes specialist doctors, the general practitioner, the staff of the reference center of the Montpellier University Hospital, the physiotherapist, the speech therapist, the dietician and the psychologist.
• Usual management including NIV.
Usual management including NIV.

Locations

Country	Name	City	State
France	Clinique du Millénaire	Montpellier
France	Uh Montpellier	Montpellier

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Montpellier	Institut National de la Santé Et de la Recherche Médicale, France, Université Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in change in functional abilities between the experimental and control groups over 6 months of follow-up.	Difference in variation of the functional capabilities assessed by the Amyotrophic lateral sclerosis functional rating scale (ALSFRS) score at Baseline (D0) and 6 months between the experimental group and the control group.; A scale to determine different aspects of functionality in patients with ALS, minimum 0 points, maximum 48 points, derived from a questionnaire with 12 questions, each of which can yield up to 4 points, higher score indicates better functionality	Between baseline and 6 months
Secondary	Difference in change in functional abilities between the experimental and control groups during 3 months of follow-up (Between 3 months and 6 months).	Difference in variation of the functional capabilities assessed by the Amyotrophic lateral sclerosis functional rating scale (ALSFRS) score at 3 month and 6 month between the experimental group and the control group.; A scale to determine different aspects of functionality in patients with ALS, minimum 0 points, maximum 48 points, derived from a questionnaire with 12 questions, each of which can yield up to 4 points, higher score indicates better functionality	Between 3 months and 6 months
Secondary	Difference in change in functional abilities between the experimental and control groups during 3 months of follow-up (Between Baseline and 3 months).	Difference in variation of the functional capabilities assessed by the ALSFRS score at Baseline (D0) and 3 month between the experimental group and the control group.; A scale to determine different aspects of functionality in patients with ALS, minimum 0 points, maximum 48 points, derived from a questionnaire with 12 questions, each of which can yield up to 4 points, higher score indicates better functionality	Between Baseline and 3 months
Secondary	Evolution of dyspnea between the 2 groups between baseline and 3 months	Dyspnea assessed by modified Borg scale. Minimum is 0 (best). Maximum is 10 (worse).	Between Baseline and 3 months
Secondary	Evolution of dyspnea between the 2 groups between baseline and 6 months	Dyspnea assessed by modified Borg scale. Minimum is 0 (best). Maximum is 10 (worse).	Between Baseline and 6 months
Secondary	Evolution of Quality of life between the 2 groups between baseline and 3 months	Quality of life assessed by the EuroQol-5 Dimensions (EQ5D) scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.	Between Baseline and 3 months
Secondary	Evolution of Quality of life between the 2 groups between baseline and 6 months	Quality of life assessed by the EQ5D scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.	Between Baseline and 6 months
Secondary	Evolution of evaluation of Anxiety and depression between the 2 groups between baseline and 3 months	Anxiety and depression assessed by the Hospital Anxiety and Depression (HAD) scale.; The HAD results in a score ranging from 0 (low anxiety or depression) to 21 (strong anxiety or depression).	Between Baseline and 3 months
Secondary	Evolution of evaluation of Anxiety and depression between the 2 groups between baseline and 6 months	Anxiety and depression assessed by the HAD scale. The HAD results in a score ranging from 0 (low anxiety or depression) to 21 (strong anxiety or depression).	Between Baseline and 6 months
Secondary	Evolution of Patient satisfaction between the 2 groups between baseline and 3 months	Patient satisfaction assessed by the CSQ-8 (Consumer satisfaction questionnaire) Minimal score is 8 and maximal score is 32. The best score is 32, that mean that patient is satisfied.	Between Baseline and 3 months
Secondary	Evolution of Caregivers satisfaction between the 2 groups between baseline and 3 months	Caregivers satisfaction assessed by the CSQ-8. Minimal score is 8 and maximal score is 32. The best score is 32, that mean that patient is satisfied.	Between Baseline and 3 months
Secondary	Evolution of Patient satisfaction between the 2 groups between baseline and 6 months	Patient satisfaction assessed by the CSQ-8. Minimal score is 8 and maximal score is 32. The best score is 32, that mean that patient is satisfied.	Between Baseline and 6 months
Secondary	Evolution of Caregivers satisfaction between the 2 groups between baseline and 6 months	Caregivers satisfaction assessed by the CSQ-8. Minimal score is 8 and maximal score is 32. The best score is 32, that mean that patient is satisfied.	Between Baseline and 6 months
Secondary	Evolution of Anthropometric criteria between the 2 groups between baseline and 3 months (Weight measurements)	Weight measurements	Between Baseline and 3 months
Secondary	Evolution of Anthropometric criteria between the 2 groups between baseline and 3 months (BMI)	BMI	Between Baseline and 3 months
Secondary	Evolution of Anthropometric criteria between the 2 groups between baseline and 6 months (weight measurements)	weight measurements	Between Baseline and 6 months
Secondary	Evolution of Anthropometric criteria between the 2 groups between baseline and 6 months (BMI)	BMI	Between Baseline and 6 months
Secondary	Evaluation of the quality and tolerance of NIV between the 2 groups at 3 months	The quality and tolerance of NIV assessed by the S3-NIV score. Score 0 to 10, lower units represent worse outcome.	At 3 months
Secondary	Evaluation of the quality and tolerance of NIV between the 2 groups at 6 months	The quality and tolerance of NIV assessed by the S3-NIV score. Score 0 to 10, lower units represent worse outcome.	At 6 months
Secondary	Evaluation of the effectiveness of NIV between the 2 groups at 3 months assessed by nocturnal oximetry	The effectiveness of NIV assessed by nocturnal oximetry	At 3 months
Secondary	Evaluation of the effectiveness of NIV between the 2 groups at 6 months assessed by nocturnal oximetry	The effectiveness of NIV assessed by nocturnal oximetry	At 6 months
Secondary	Evaluation of the effectiveness of NIV between the 2 groups at 3 months assessed by nocturnal capnography	The effectiveness of NIV assessed by nocturnal capnography	At 3 months
Secondary	Evaluation of the effectiveness of NIV between the 2 groups at 6 months assessed by nocturnal capnography	The effectiveness of NIV assessed by nocturnal capnography	At 6 months
Secondary	Evaluation of the NIV parameters between the 2 groups at 3 months	NIV parameters obtained using data from the machine report	At 3 months
Secondary	Evaluation of the NIV parameters between the 2 groups at 6 months	NIV parameters obtained using data from the machine report	At 6 months
Secondary	Evaluation of survival between the 2 groups at 3 months	Evaluation of survival between the 2 groups at 3 months	At 3 months
Secondary	Evaluation of survival between the 2 groups at 6 months	Evaluation of survival between the 2 groups at 6 months	At 6 months
Secondary	Evaluation of time to first hospitalization between the 2 groups at 3 months	recovery of hospitalization data	At 3 months
Secondary	Evaluation of time to first hospitalization between the 2 groups at 6 months	recovery of hospitalization data	At 6 months
Secondary	Evaluation at 3 months in the experimental group of the Satisfaction of professionals with the digital solution	Satisfaction of professionals with the digital solution by a VAS (Visual Analog Scale) of satisfaction	At 3 months
Secondary	Evaluation at 6 months in the experimental group of the Satisfaction of professionals with the digital solution	Satisfaction of professionals with the digital solution by a VAS (Visual Analog Scale) of satisfaction	At 6 months
Secondary	Medico-economic evaluation: incremental cost-utility ratio	Utility will be derived from the EQ5D	6 months
Secondary	Evaluation at 3 months in the experimental group of the Patient satisfaction with the digital solution	Patient satisfaction with the digital solution assessed by a VAS (Visual Analog Scale) of satisfaction	At 3 months
Secondary	Evaluation at 6 months in the experimental group of the Patient satisfaction with the digital solution	Patient satisfaction with the digital solution assessed by a VAS (Visual Analog Scale) of satisfaction	At 6 months
Secondary	Evaluation at 3 months in the experimental group of the caregiver satisfaction with the digital solution	Caregiver satisfaction with the digital solution assessed by a VAS (Visual Analog Scale) of satisfaction	At 3 months
Secondary	Evaluation at 6 months in the experimental group of the caregiver satisfaction with the digital solution	Caregiver satisfaction with the digital solution assessed by a VAS (Visual Analog Scale) of satisfaction	At 6 months